Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand

In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the
generic version of Sunitinib oral capsules to treat kidney cancer in
India. The drug is launched at a MRP that is approximately 96 per cent
lower than the MRP (maximum retail price) compared to the innovator
brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5
mg) per month".

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-launches-kidney-cancer-treatment-drug-in-india-priced-96-lower-than-innovator-brand/articleshow/80969368.cms

Comments

Popular posts from this blog

Sunday Worship Service

Teva Regulatory Affairs Associate Job Vacancy – Apply Online

Teva Regulatory Affairs Job Vacancy – Pharma Candidates Apply